b'NGS Cancer PanelsTest Name internal tandem duplications. Coupling comprehensive MyAML - NGS Gene Panel Assaygene coverage with enhanced depth of coverage, long read lengths, and the power of our robust annotation software and bioinformatics database, MyAML identifies Assay Type the underlying somatic mutations that are present as low as 5% allelic frequency. The data and report include single Next-Generation Sequencing (NGS) base resolution of the genomic breakpoint and sequences CLIA-validated assay of mutations, facilitating optimized treatment plans and longitudinal tracking of minimal residual disease.Method Description A completed patient consent form must be submitted for each sample sent to LabPMM.Using proprietary design, the coding regions and potential genomic breakpoints within known somatic gene fusions are sequenced to an average depth of coverage ofIndications for Testing1000x. By utilizing long read lengths, the assay accuratelyAt initial diagnosis of AMLdetects and characterizes the breakpoints of structuralStratifying risk for AMLvariants and gene fusions, often with single base-pair precision. In addition, these long reads enhance the abilityMonitor and evaluate for refractory and relapsedto identify both the insertion site and DNA content of largediseaseInterpretation TurnaroundSpecimen Requirements ShippingSpecimen Time Conditions StabilityAn interpretive14 to 21 3 mL of peripheral blood inAmbient or Room Temp report will bebusiness days Heparin, EDTA or ACD Cool; do notup to 72 hoursissued indicating1 mL of bone marrow infreeze 2-8 C upthe SNVs, indels, inversions andHeparin, EDTA or ACD to 7 days translocationsCell Pellets in cell cultureidentified media or buffered solutions without fixatives1 g of purified, high qualitygenomic DNALabPMM Services Catalog 2021|51'